MedTrace Logo

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2014-01-13

Study results available
· View outcomes & findings →

Summary

The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD). Since vaccination with live vaccinia virus (VV) in individuals with AD increases the risk of EV, a yellow fever vaccine was chosen. The purpose of this study is to determine the immune response to a yellow fever vaccine in adults with AD.

Conditions

Interventions

BIOLOGICAL

Live Yellow Fever Vaccine (YFV-17D)

DRUG

YFV-17D Placebo

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Jon Hanifin, M.D. · Oregon Health and Science University

  • Mark Slifka, Ph.D. · Oregon Health and Science University

  • Eric Simpson, M.D. · Oregon Health and Science University

  • Henry Milgrom, M.D. · National Jewish Health

  • Richard Gallo, M.D., Ph.D. · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
27 Years
Max Age
43 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723489 on ClinicalTrials.gov